RECENT FUNDING
  1. Recent Funding
  2. Investors
  3. Cancer Research Horizons
C

Cancer Research Horizons portfolio

Cancer Research Horizons has 2 portfolio companies on record at Recent Funding, with 1 investment in the last 12 months.

Type: Investor.
Portfolio on Recent Funding: 2.
Deals, last 12 months: 1.
Capital in their rounds: $210M.
Latest deal: Alethio Therapeutics · Nov 5, 2026.
About this page

Its most recent investment on record is Alethio Therapeutics's $90M Series A round in November 2026, alongside University of Oxford, RA Capital Management, Oxford Science Enterprises and 1 other. By category, its portfolio leans toward Health and bio (2). It has co-invested with Sofinnova Partners, RA Capital Management and Oxford Science Enterprises, most often Sofinnova Partners (2 rounds).

What Cancer Research Horizons invests in

How Cancer Research Horizons invests

StageDealsCapital in rounds
Series A 2 100%$210M
YearDealsCapital in rounds
2024 1 50%$120M
2026 1 50%$90M

Cancer Research Horizons portfolio companies

CompanyRound with Cancer Research HorizonsTotal raisedLatest raise
AAlethio Therapeutics
Health and bio
 Series A · $90M$90MNov 5, 2026
Series A
MMyricx Bio
Health and bio
 Series A · $120M$120MJul 8, 2024
Series A

Most frequent co-investors

Similar investors

Investors whose portfolios on Recent Funding center on the same category (Health and bio).

How this is counted

Share is of the 2 rounds on Recent Funding that name Cancer Research Horizons. Rounds with no announced date are left out of the year split, and "round" is a round whose stage is not on file.

Portfolio companies are the companies on Recent Funding with a round that lists Cancer Research Horizons, which is a subset of its real portfolio. API: /api/v1/investors/cancer-research-horizons (get a free API key). More: the most active VC firms and new venture capital funds.